Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial on the Effectiveness and Adherence of Modified Alternate-day Calorie Restriction (MACR) in Improving Activity of Non-Alcoholic Fatty Liver Disease
Brief Summary: There is no effective therapy for non-alcoholic fatty liver disease (NAFLD), although intensive calorie restriction is typically recommended but dietary adherence is an issue. Currently, there are no studies had been focusing the effect of Modified Alternate Day Calorie Restriction in NAFLD patient focusing on changes in liver steatosis and fibrosis.


Options:
A: Arm Label: Intermittent Fasting; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Meal Replacement | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Meal Replacement; Assigned to Arm(s): Intermittent Fasting
B: Arm Label: Calorie restriction (MACR); Type: EXPERIMENTAL; Interventions: Behavioral: Calorie restriction (MACR) | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Calorie restriction (MACR); Assigned to Arm(s): Calorie restriction (MACR)
C: Arm Label: Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68); Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68); Type: EXPERIMENTAL; Interventions: Drug: placebo | Arm Label: Liraglutide Placebo, no Pre-diabetes; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Liraglutide 3.0mg, Pre-diabetes; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Liraglutide Placebo, Pre-diabetes; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68) | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68), Liraglutide Placebo, no Pre-diabetes | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide 3.0mg, Pre-diabetes | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Liraglutide Placebo, Pre-diabetes
D: Arm Label: Isocaloric diet; Type: ACTIVE_COMPARATOR; Interventions: Other: Bed rest, Other: OGTT, Other: IVGTT, Other: Cognitive testing, Other: Muscle and fat biopsies, Other: Dual-energy X-ray Absorptiometry (DXA) scan, Other: MRI | Arm Label: Alternate daily fasting; Type: ACTIVE_COMPARATOR; Interventions: Other: Bed rest, Other: OGTT, Other: IVGTT, Other: Cognitive testing, Other: Muscle and fat biopsies, Other: Dual-energy X-ray Absorptiometry (DXA) scan, Other: MRI | Intervention Type: OTHER; Name: Bed rest; Assigned to Arm(s): Alternate daily fasting, Isocaloric diet | Intervention Type: OTHER; Name: OGTT; Assigned to Arm(s): Alternate daily fasting, Isocaloric diet | Intervention Type: OTHER; Name: IVGTT; Assigned to Arm(s): Alternate daily fasting, Isocaloric diet | Intervention Type: OTHER; Name: Cognitive testing; Assigned to Arm(s): Alternate daily fasting, Isocaloric diet | Intervention Type: OTHER; Name: Muscle and fat biopsies; Assigned to Arm(s): Alternate daily fasting, Isocaloric diet | Intervention Type: OTHER; Name: Dual-energy X-ray Absorptiometry (DXA) scan; Assigned to Arm(s): Alternate daily fasting, Isocaloric diet | Intervention Type: OTHER; Name: MRI; Assigned to Arm(s): Alternate daily fasting, Isocaloric diet

Answer: B